Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥6,240 JPY
Change Today +138.00 / 2.26%
Volume 3.7M
As of 2:00 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - ¥6,657
52 Week Low
10/17/14 - ¥4,338
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Corporate Strategy ...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Second Quarter and Full Year 2015

Takeda Pharmaceutical Company Limited provided dividend guidance for the second quarter and full year 2015. For the second quarter of 2015, the company expects to pay a dividend of JPY 90.00 per share. For the year 2015, the company expects to pay a dividend of JPY 90.00 per share.

Takeda Pharmaceutical Company Limited Reports Consolidated Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Full Year of 2015

Takeda Pharmaceutical Company Limited reported consolidated earnings results for the first quarter of 2015. For the quarter, revenue was JPY 446.3 billion against JPY 411.1 billion a year ago. Core earnings was JPY 86.9 billion against JPY 84.3 billion a year ago. Net profit was JPY 24.6 billion against JPY 33.4 billion. Operating Profit was JPY 49.6 billion against JPY 63.7 billion a year ago. EPS was JPY 31 against JPY 42 a year ago. Core EPS was JPY 67.48 against JPY 66.60 a year ago. Profit before tax was JPY 48.7 billion against JPY 60 billion a year ago. Underlying revenue was JPY 449.9 against JPY 424.2 a year ago. Net cash from operating activities was JPY 18.6 billion against JPY 20 billion a year ago. Operating free cash flow was JPY 3 billion against negative operating free cash flow of JPY 28 billion a year ago. Capital expenditure was JPY 10 billion against JPY 10.8 billion a year ago. Acquisition of intangible assets was JPY 5.6 billion against JPY 29.2 billion a year ago. Net debt was JPY 90.1 billion against JPY 11.5 billion a year ago. The company affirming guidance for the year 2015, low single-digit underlying revenue growth , with underlying core earnings growth higher than underlying revenue growth, and underlying core EPS growth higher than underlying core earnings growth.

Drugs for Neglected Diseases Initiative and Takeda Pharmaceutical Company Limited Collaborate for Lead Optimization for Aminopyrazole Series for Visceral Leishmaniasis

Drugs for Neglected Diseases initiative and Takeda Pharmaceutical Company Limited announced that they have signed an agreement to collaborate in the 'Lead Optimization Program' aimed at identifying the best compound among aminopyrazole series for developing an innovative drug for the treatment of visceral leishmaniasis (VL). The program is being funded by Global Health Innovative Technology Fund (GHIT). GHIT Fund is investing approximately ¥400 million into DNDi for the program. DNDi and Takeda are working on the lead optimization of the aminopyrazole series. In preclinical trials, the aminopyrazole series exhibited good antiparasitic activity, and are expected to be highly safe and effective. DNDi and Takeda consider that short-course oral administration of the drug is effective for the treatment, and therefore it is expected to be a novel drug which will be different from the existing therapeutics for VL. In addition to this collaboration agreement, DNDi and Takeda entered into partnership agreements such as the 'drug discovery booster for accelerating and promoting the discovery of new drugs for treating leishmaniasis and Chagas disease'. DNDi and Takeda aim to contribute towards treating 'Neglected Tropical Diseases' through these efforts.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥6,240.00 JPY +138.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.69 USD -0.08
Baxter International Inc $40.08 USD +0.07
Becton Dickinson and Co $152.15 USD +0.15
Biogen Inc $318.78 USD +1.78
Merck KGaA €92.61 EUR -0.64
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book 2.2x
Price/Cash Flow 155.8x
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at